Literature DB >> 20591633

Prognostic significance of age in the radical treatment of oesophageal cancer with surgery or chemoradiotherapy: a prospective observational cohort study.

Ll Davies1, W G Lewis, D T Arnold, X Escofet, G Blackshaw, S Gwynne, M Evans, S A Roberts, I Appadurai, T D Crosby.   

Abstract

AIMS: To compare the outcomes of stage-directed surgical therapy and chemoradiotherapy (CRT) for oesophageal cancer and to determine if a significant age-treatment interaction exists to guide therapy.
MATERIALS AND METHODS: Five hundred and eight consecutive patients with oesophageal cancer suitable for radical treatment based on radiological stage and performance status were studied (275 surgery; 93 surgery alone, 131 neoadjuvant chemotherapy, 51 neoadjuvant CRT and 233 definitive CRT). The primary measure of outcome was survival.
RESULTS: Thirty-day mortality rates and 2-year survival after surgery and CRT in patients<70 years were 2.4 and 57.5%, respectively, compared with 0 (P=0.207) and 47.3% (P=0.011), respectively. Thirty-day mortality rates and 2-year survival after surgery and CRT in patients>or=70 years were 7.0 and 45.1%, respectively, compared with 0 (P=0.029) and 46.3% (P=0.992), respectively. Multivariate analysis including only surgical patients in the model revealed three factors to be independently and significantly associated with survival; endoscopic ultrasound (EUS) T stage (P=0.033), EUS lymph node metastasis count (>or=2 versus 0: hazard ratio 1.67, 95% confidence interval 1.06-2.92, P=0.026), and age>or=70 years (hazard ratio 1.51, 95% confidence interval 1.05-2.16, P=0.025).
CONCLUSION: Overall survival for patients treated with surgery was strongly age dependent around the age of 70 years, and patients>or=70 years with oesophageal cancer should be aware that outcomes after CRT are similar to those after surgery. Copyright (c) 2010 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20591633     DOI: 10.1016/j.clon.2010.05.023

Source DB:  PubMed          Journal:  Clin Oncol (R Coll Radiol)        ISSN: 0936-6555            Impact factor:   4.126


  4 in total

1.  Patient Selection for Oesophagectomy: Impact of Age and Comorbidities on Outcome.

Authors:  Gregory O'Grady; Ahmer M Hameed; Tony C Pang; Emma Johnston; Vincent T Lam; Arthur J Richardson; Michael J Hollands
Journal:  World J Surg       Date:  2015-08       Impact factor: 3.352

2.  Small proline-rich repeat protein 3 enhances the sensitivity of esophageal cancer cells in response to DNA damage-induced apoptosis.

Authors:  Aiping Luo; Hongyan Chen; Fang Ding; Yu Zhang; Mingrong Wang; Zefen Xiao; Zhihua Liu
Journal:  Mol Oncol       Date:  2013-06-13       Impact factor: 7.449

3.  Effect of Extending the Original Eligibility Criteria for the CROSS Neoadjuvant Chemoradiotherapy on Toxicity and Survival in Esophageal Cancer.

Authors:  E C de Heer; J B Hulshoff; D Klerk; J G M Burgerhof; D J A de Groot; J Th M Plukker; G A P Hospers
Journal:  Ann Surg Oncol       Date:  2017-02-10       Impact factor: 5.344

4.  Long-Term Survival in Nonsurgical Esophageal Cancer Patients Who Received Consolidation Chemotherapy Compared With Patients Who Received Concurrent Chemoradiotherapy Alone: A Systematic Review and Meta-Analysis.

Authors:  Xiaojie Xia; Zeyuan Liu; Qin Qin; Xiaoke Di; Zhaoyue Zhang; Xinchen Sun; Xiaolin Ge
Journal:  Front Oncol       Date:  2021-01-07       Impact factor: 6.244

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.